In our prospective multicenter study, we investigated the prognostic value of pretreatment plasma levels of soluble TARC, sCD30, sCD163, and sIL-6 in 162 newly diagnosed cHL patients and developed a model incorporating these biomarkers for risk prediction across all stages. The gene discussed is CCL17; the disease is classic Hodgkin lymphoma.